NAT10 and hepatocellular carcinoma: Gene expression for each of these 13 candidates is significantly dysregulated in liver disease (MASLD and cirrhosis) and/or HCC (Fig. 7G), with dysregulated levels of several of these genes associated with overall patient survival in HCC (i.e., CDKN2C, IGF1, MCM4, MCM6, NAT10, ORC4, SMARCAD1, TAF6, and TRAF2) (fig.